Keywords: incara, starts, trials, ibd, drug, pharmaceuticals, started
Incara starts trials of IBD drug
Article | 05 November 1999
Incara Pharmaceuticals has started testing its heparin-derivedoligosaccharide product, OP2000, in healthy subjects. OP2000, which has both antithrombotic and anti-inflammatory properties, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
